Search PubMed⌕ Search

Biomedical subjects

A J Marcus

Publications and source records attributed to A J Marcus.

At least 73 records · Page 4Linked to original sources
PubMed1986

Phospholipid metabolism in human neutrophils activated by N-formyl-methionyl-leucyl-phenylalanine. Degranulation is not required for release of arachidonic acid: studies with neutrophils and neutrophil-derived cytoplasts.

Neutrophils respond to chemoattractants by aggregating, degranulating, remodelling of phospholipids and releasing arachidonic acid. To determine whether ligand-induced remodelling of phospholipids depends on redistribution of intracellular organelles (degranulation), we compared phospholipid remodelling of human neutrophils with that of neutrophil-derived cytoplasts. Cytoplasts, organelle-depleted vesicles of cytosol surrounded by plasmalemma, cannot degranulate. Without a stimulus, [3H]arachidonate was incorporated preferentially into phosphatidylinositol (PI) and phosphatidylcholine (PC). Exposure of cytoplasts and neutrophils prelabelled with [3H]arachidonate or [14C]glycerol to fMet-Leu-Phe (10(-7) M) induced rapid changes in distribution of label and mass of individual phospholipids: [3H]arachidonate in phosphatidic acid (PA) increased 500% (120 s), [14C]glycerol incorporation and mass of PA approached 200% of unstimulated values, and [3H]arachidonate in PI decreased continuously; these data are compatible with activity of a PI/PA cycle. However, the mass of PI in both preparations and [14C]glycerol label in intact neutrophils increased initially (5 s), suggesting net synthesis and mobilization of more than one pool of PI. Heterogeneity of PC pools was also observed: [3H]arachidonate was lost from PC immediately upon addition of stimulus, whereas mass and [14C]glycerol values increased. Thus, net phospholipid synthesis, redistribution of arachidonate and activation of the PI/PA cycle are immediate responses of the neutrophil to receptor occupancy by chemoattractants. Furthermore, the similarity in response to fMet-Leu-Phe of neutrophils and granule-free cytoplasts indicates that these processes are independent of degranulation.

Arachidonic Acids↗
PubMed1986

Enhancement of mononuclear procoagulant activity by platelet 12-hydroxyeicosatetraenoic acid.

Platelets induce generation of procoagulant tissue factor activity (TFa) by mononuclear leukocytes, and also enhance the TFa induced by endotoxin. Our present investigation demonstrated that arachidonic acid, which by itself had no effect on mononuclear TFa, greatly enhanced platelet-induced TFa. The effect was concentration dependent for both platelets and arachidonate (1-20 microM); other fatty acids tested were inactive. The enhancing effect of arachidonate was more pronounced if platelets were exposed to aspirin, suggesting lipoxygenase product involvement. Production of 12-hydroxyeicosatetraenoic acid (12-HETE) was demonstrated biochemically in aspirin-treated platelet/arachidonate/mononuclear cell preparations that generated high levels of TFa. The enhancing role of 12-HETE was verified as follows. Addition of platelet-derived or synthetic 12-HETE amplified endotoxin-induced TFa more than threefold. Other lipoxygenase products were inactive. Enhancement of mononuclear cell TFa by 12-HETE represents a newly described biological function for this eicosanoid in cell-cell interactions between platelets and mononuclear cells.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗
PubMed1986

Transcellular metabolism of eicosanoids.

In this chapter, current concepts of eicosanoid biochemistry and function have been summarized. Emphasis has been placed on the importance of ascertaining a complete profile of eicosanoids synthesized by a given tissue under varying conditions of stimulation. The concept of transient intermediates, which are involved in each of the known pathways, was reviewed. Such intermediates can also represent substrate for cell-cell interactions, which have been classified and discussed. Knowledge of the synthetic mechanisms, metabolism, and catabolism of eicosanoids has surpassed our comprehension of their biologic actions. It can be speculated that eicosanoids reinforce or synergize normal homeostatic mechanisms that might proceed less effectively in their absence but occur more efficiently when they are produced. Incomplete comprehension of the functional role of eicosanoids has retarded the development of definitive pharmaceutical approaches toward inhibition or stimulation of eicosanoid production in pathophysiologic situations. With regard to thrombosis, the inflammatory response and host-defense mechanisms, leukotrienes, which have been shown to act on vascular endothelium and smooth muscle, may play an important role in occlusive vascular disease. Since leukotrienes and other hydroxy acids such as 12-HETE are not inhibited by aspirin or nonsteroidal anti-inflammatory agents, development of a unifying concept is difficult. It appears that we are approaching a point in time for reevaluation and reassessment of the role of the eicosanoid pathway in hemostasis and thrombosis. Most importantly, recent eicosanoid research has provided answers to biologic phenomena that were not explicable in the past and also explains why therapeutic trials in occlusive vascular disease were not as successful as predicted on theoretical grounds.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗
PubMed1985

Eicosanoids as bioregulators in clinical medicine.

Formation of eicosanoids in stimulated cells and tissues is a ubiquitous phenomenon, but the precise physiologic or pathophysiologic role of these autacoids has not yet been defined. In contrast, understanding of synthetic mechanisms, metabolism, and catabolism of eicosanoids seems to have surpassed understanding of their pharmacologic actions. Early clinical research involving eicosanoids focused on reactions of the cyclo-oxygenase pathway, which are inhibitable by nonsteroidal anti-inflammatory drugs. The lipoxygenase pathway, which appears to be an important component of the allergic and inflammatory response, represents a new area of clinical research.

Arachidonic Acids↗
PubMed1985

Inhibition of platelet function in thrombosis.

Accumulating experimental and clinical evidence indicates that a time for reappraisal of therapeutic modalities designed to inhibit the eicosanoid pathway as it may affect vascular disease may be approaching. Pharmacologic agents originally used were chosen because they were capable of suppressing platelet functions such as aggregation, release, and adhesion. The goals of clinical trials were to evaluate medications that would prevent or reduce platelet accumulation in critically located blood vessels of the heart, brain, and extremities and on vascular prostheses. Evaluation of results of therapeutic trials has been difficult and this is superimposed on less-than-complete knowledge of the basic pharmacology of the drugs that have been used. Participation of neutrophils and possibly macrophages in the thrombotic process is now well recognized on morphologic grounds. Because different cell types such as platelets, neutrophils, and endothelial cells have been shown to interact biochemically by sharing precursors and intermediates of the eicosanoid pathway, the pharmacologic approach to inhibition of vascular disease may require reevaluation. Neutrophils appear to lack a cyclooxygenase pathway but serve as a source of the lipoxygenase product leukotriene B4 (LTB4). Actions of LTB4 include neutrophil aggregation, adhesion of neutrophils to endothelial cells, chemotaxis, chemokinesis, and plasma exudation. We have demonstrated in vitro that released free arachidonic acid from aspirin-treated platelets can serve as a source of neutrophil LTB4. Leukotrienes C4, D4, and E4 are agonists for various functions of vascular endothelium and smooth muscle. Most pharmacologic agents used in the treatment of vascular diseases inhibit the cyclooxygenase pathway.(ABSTRACT TRUNCATED AT 250 WORDS)

Arachidonic Acids↗
PubMed1984

Production of metabolic products of arachidonic acid during cell-cell interactions.

We studied interactions of human platelets and neutrophils with particular reference to the arachidonic acid pathway. Suspensions of [3H]arachidonate-labeled platelets and unlabeled neutrophils were stimulated with ionophore A23187. We detected several radioactive arachidonate metabolites, which are not produced by platelets alone. These included [3H]-labeled leukotriene B4 (LTB4), dihydroxy-eicosatetraeonic acid (DiHETE), and 5-hydroxy-eicosatetraenoic acid (5-HETE). DiHETE was formed when the platelet product [3H]12-HETE was added to ionophore-stimulated neutrophils. In addition, DiHETE was the major metabolite when [3H]5-HETE, a neutrophil arachidonate product, was added to stimulated platelets. We therefore suggest that upon stimulation, platelet-derived arachidonate can serve as precursor for the neutrophil-derived eicosanoids LTB4 and 5-HETE, and the platelet-derived product 12-HETE can be metabolized to DiHETE by stimulated human neutrophils. More recently we have shown that 12-HETE from thrombin-stimulated platelets can also be metabolized to a new product, 12,20-DiHETE, by unstimulated human neutrophils. It would appear that the platelet and neutrophil lipoxygenase pathways take part in cell-cell interactions--an observation that suggests a role for the neutrophils that are present in hemostatic plugs, thrombi, and inflammatory processes.

Arachidonate Lipoxygenases↗
PubMed1984

12S,20-dihydroxyicosatetraenoic acid: a new icosanoid synthesized by neutrophils from 12S-hydroxyicosatetraenoic acid produced by thrombin- or collagen-stimulated platelets.

A new metabolite of arachidonic acid, formed during interaction between thrombin- or collagen-stimulated platelets and unstimulated neutrophils, has been demonstrated by both thin-layer radiochromatography and high-performance liquid chromatography. Production of the 3H-labeled metabolite in combined suspensions containing [3H]arachidonate-labeled platelets and unlabeled neutrophils from aspirin-treated donors suggested that platelet 3H-labeled 12S-hydroxy-5,8-cis,10-trans,14-cis-icosatetraenoic acid (12-HETE) was the precursor. This was confirmed by identification of the same product when purified 12-[3H]HETE was added directly to unstimulated neutrophils. Hydrogenation and oxidation of the isolated product, followed by gas chromatography-mass spectrometry showed the structure to be 12S,20-dihydroxyicosatetraenoic acid. These experiments further show that platelet stimuli known to occur in vivo may initiate metabolic interactions between different cell types via the arachidonic acid pathway.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗
PubMed1984

Production of arachidonic acid lipoxygenase products during platelet-neutrophil interactions.

We studied interactions of human platelets and neutrophils with particular reference to the arachidonic acid pathway. Suspensions of [3H]-arachidonate-labeled platelets and unlabeled neutrophils were stimulated with ionophore A23187. We detected several radioactive arachidonate metabolites, which are not produced by platelets alone. This included [3H]-labeled leukotriene B4 (LTB4), dihydroxyeicosatetraenoic acid (DHETE) and 5-hydroxyeicosatetraenoic acid (5-HETE). When the platelet product, [3H]12-HETE, was added to ionophore-stimulated neutrophils, DHETE was formed. In addition, when [3H]5-HETE, a neutrophil arachidonate product, was added to stimulated platelets, DHETE was the major metabolite. We, therefore, suggest that upon stimulation, the platelet derived arachidonate can serve as precursor for the neutrophil-derived eicosanoids LTB4 and 5-HETE and that the platelet-derived product 12-HETE can be metabolized to DHETE by stimulated human neutrophils. It would appear that the platelet and neutrophil lipoxygenase pathways take part in cell-cell interactions - an observation which suggests a role for the neutrophils which are present in hemostatic plugs, thrombi and inflammatory processes.

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid↗
PubMed1983

Changes in phosphatidylinositol and phosphatidic acid in stimulated human neutrophils. Relationship to calcium mobilization, aggregation and superoxide radical generation.

Human neutrophils aggregate and release mediators of inflammation, such as active oxygen species and lysosomal enzymes, when exposed to the chemoattractant, fMet-Leu-Phe, or the tumor promotor, phorbol myristate acetate. In order to 'stage' events which may lead to such neutrophil responses, we determined the temporal relationship between stimulus-induced changes in the endogenous phospholipids phosphatidylinositol (PI) and phosphatidic acid, the mobilization of calcium, and the onset of aggregation and generation of superoxide anion during the initial 2 min of cell activation. Within 5 s after addition of fMet-Leu-Phe (10(-7) M) neutrophils accumulated phosphatidic acid and the levels of PI decreased, as determined by two-dimensional thin-layer chromatography and phosphorus determinations. By 5 s, phosphatidic acid levels rose approximately 3.5-fold and at 15 s the loss of PI exceeded the quantity of phosphatidic acid generated. In response to phorbol myristate acetate (1 microgram/ml), however, changes in PI or phosphatidic acid were not observed until after 60 s. Accumulation of phosphatidic acid in fMet-Leu-Phe-stimulated cells was not inhibited by chelation of extracellular calcium. Neutrophils exposed to either fMet-Leu-Phe or phorbol myristate acetate also showed rapid decrements in fluorescence of cell-associated chlorotetracycline (used as an indirect probe of mobilization of intracellular membrane-associated calcium) and took up 45Ca2+ from the extracellular medium (under 60 s). The results indicate that changes in calcium mobilization, together with the alterations in phospholipid metabolism (under 5 s) anteceded aggregation and the generation of O2-. (10-15 s) induced by fMet-Leu-Phe. In contrast, when neutrophils were exposed to phorbol myristate acetate, changes in PI and phosphatidic acid (over 60 s) were observed after the mobilization of calcium (under 5 s) and the onset of O2-. generation and aggregation (30-35 s).

Calcium↗
PubMed1981

Fatty acid composition of phosphatidylinositol and phosphatidic acid in stimulated platelets. Persistence of arachidonyl-stearyl structure.

The fatty acid composition of phosphatidylinositol (PI), phosphatidic acid (PA), and the free fatty acid pool of human platelets was studied as a function of time following thrombin stimulation. Upon addition of thrombin, the total amount of fatty acids in PI decreased sharply, then rose toward basal levels, while that of PA showed an inverse pattern. However, the percentage distribution of fatty acids in stimulated as well as unstimulated PI and those in stimulated PA remained relatively constant: stearic and arachidonic acids accounted for 90 and 80% of the total in PI and PA, respectively. These data suggest that in stimulated human platelets PI and PA are interconverted via the "PI cycle." The time course of changes in PI and PA may suggest that the levels of arachidonyl-stearyl PA are involved in regulation of the resynthesis of arachidonyl-steryl PI. In contrast to PI and PA, the free fatty acid pool showed sharp increases in the five major platelet fatty acids: arachidonate, stearate, palmitate, oleate, as well as linoleate. These data suggest that most of the fatty acids liberated upon platelet stimulation are not derived via PI metabolism but by other mechanisms.

Arachidonic Acid↗